InCode BioPharmaceutics

BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality. BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007. BioVascular's second product utilizes a mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Sunzen Biotech Berhad ("Sunzen Biotech"‚) is an animal health specialist, focused on developing, manufacturing and marketing animal health care products. The company market a range of animal health products which includes feed additives, nutritional feed supplements, veterinary pharmaceuticals, animal vaccines and other animal health care products for livestock such as poultry, swine, goats and cattle, as well as companion animals. The company develop and manufacture non-antibiotic animal health products that comply with international safety standards to ensure public safety. And in recognition of the company's focused Research and Development in non-antibiotic animal biotechnology, Sunzen Biotech has been accorded BioNexus Status, which entitles Sunzen to tax incentives and other privileges specified under the Bionexus bill of guarantees, from the Malaysian Biotechnology Corporation. Sunzen is also the sole distributor for Pfizer Animal Health products in Malaysia, Singapore, andnBrunei. The company are proud to say that today "Sunzen"‚ products are supplied to feed millers and livestock producers in Malaysia and across the region.